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anglais
BACKGROUND: To date, no predictive biomarker for the efficacy of FOLFIRINOX in
metastatic pancreatic adenocarcinoma has been demonstrated. Deficiency in O-
methylguanine-DNA methyltransferase (MGMT) has been associated with a
therapeutic response in endocrine tumors of the pancreas and the lack of expression
of protein 53 (p53) could interfere with the action of MGMT.
OBJECTIVE: The aim of our study was to assess the prevalence of MGMT and p53 in
patients with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX as a
first-line treatment and to investigate their association with therapeutic response
and survival.
PATIENTS AND METHODS: The immunohistochemical expression of MGMT was
recorded as present or absent and the expression of p53 was semi-quantitatively
scored in 30 patients with metastatic pancreatic adenocarcinoma, at Angers Hospital
in France between September 2011 and June 2015. Clinical and radiologic data were
collected retrospectively.
RESULTS: The presence or absence of MGMT expression entailed no significant
differences in response rate. Median values of progression-free survival (PFS) and
overall survival (OS) were lower in patients with MGMT expression, but sample size
is too small to conclude that there is a statistically significant difference. No
significant relationship for response rate and PFS was observed in relation with p53
expression. By contrast, patients with a strong tumor expression of p53 had a
significantly lower OS compared to patients with no or weak expression of the
protein (p = 0.027). There was a positive correlation between the expression of p53
and MGMT (p = 0.08).
CONCLUSIONS: These preliminary findings suggest that for patients treated with
FOLFIRINOX as a first-line treatment for metastatic pancreatic adenocarcinoma, the
immunohistochemical evaluation of MGMT could not predict the clinical outcome;
however, the survival was not significant probably because of the under-powered
study (due to small sample size). A strong tumor expression of p53 is associated with
a poor prognosis of OS.
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